🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Lipoprotein Disorder

Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke NCT06649240NA46 sites📍 Ansan📍 Anyang📍 Busan Seoul National University Hospital · Tests: Statins and/or Ezetimibe, PCSK9 inhibitor Testing for Increased Lipoproteins (a) [LP(a)] in Lymphedema Patients: Li-LY NCT05962827NA2 sites📍 Nice📍 Nice Centre Hospitalier Universitaire de Nice · Tests: lipoprotein (a) LCAT (Lecithin Cholesterol Acyl Transferase) Natural History Study NCT06217588n/a1 site📍 Philadelphia University of Pennsylvania · Tests: Demographics, diagnosis type, genotype, lipid profile, renal function profile, treatment allocation, ophthalmology exam… The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Myocardial Deformation NCT07324902n/a2 sites📍 Athens📍 Athens University of Athens AI-assisted CT for Risk Stratification in Coronary Artery Disease (ACTION) NCT07577609n/a1 site📍 Galway University of Galway Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study) NCT07359105NA2 sites📍 Seoul📍 Seoul Sin Gon Kim · Tests: Moderate-intensity statin monotherapy, Ezetimibe or ezetimibe-statin combination therapy Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia NCT06858332n/a20 sites📍 Chelyabinsk📍 Chelyabinsk📍 Kaluga Novartis Pharmaceuticals · Tests: Atorvastatin, Simvastatin, Rozuvastatin, Ezetimibe, Niacin Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) NCT07157774Phase 3804 sites📍 Birmingham📍 Apache Junction📍 Gilbert Eli Lilly and Company · Tests: Muvalaplin, Placebo Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients? NCT06471036NA1 site📍 Minneapolis Duke University · Tests: Care Champion Intervention Effect of Consuming n-3 Polyunsaturated Fatty Acids Rich Foods on Triglyceride Concentration and Lipoprotein Composition NCT07004777NA1 site📍 Mexico City Instituto Nacional de Ciencias Medicas y Nutricion Salvador… · Tests: Isocaloric diet including chia and pumpkin seeds, Isocaloric diet Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions NCT06676046n/a1 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia NCT06597006Phase 319 sites📍 San Francisco📍 Washington D.C.📍 St Louis Novartis Pharmaceuticals · Tests: Inclisiran, Placebo Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids NCT04485871NA1 site📍 Montreal Institut de Recherches Cliniques de Montreal · Tests: Omega-3 fatty acids A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. NCT07619131Phase 3152 sites📍 Dothan📍 Chandler📍 Phoenix AstraZeneca · Tests: Laroprovstat, Rosuvastatin 1, Rosuvastatin 2, Laroprovstat/Rosuvastatin 1, Placebo to match rosuvastatin Electronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement Implementation Study NCT07685639NA2 sites📍 Edmonton📍 Edmonton University of Alberta · Tests: Pharmacist-led lipid optimization pathway A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia NCT07619118Phase 345 sites📍 Sun City West📍 Gardena📍 Lomita AstraZeneca · Tests: laroprovstat/rosuvastatin 1, laroprovstat/rosuvastatin 2, laroprovstat/rosuvastatin 3, laroprovstat/rosuvastatin 4, Pla… The Effect of Propolis Administration on Cholesterol Level in Diabetic Type 2 Patients NCT06903546Phase 41 site📍 Jakarta Universitas Indonesia · Tests: Propolis drops, Placebo Differential Thrombogenesis by EPA and DHA Mediated by HDL NCT06494488EARLY Phase 11 site📍 Providence The Miriam Hospital · Tests: EPA, DHA A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia NCT06980428Phase 16 sites📍 Glendale📍 Inverness📍 Jacksonville AstraZeneca · Tests: AZD4954, Placebo Causes and Natural History of Dyslipidemias NCT00353782n/a1 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia NCT06597019Phase 366 sites📍 San Francisco📍 San Francisco📍 Washington D.C. Novartis Pharmaceuticals · Tests: Inclisiran, Placebo The Effect of Improved Glycemic Control on the Composition and Function of High-Density Lipoproteins (HDL) in Patients With Type 1 Diabetes NCT07564752n/a1 site📍 Dijon Centre Hospitalier Universitaire Dijon · Tests: Blood test, Urine sample Lipoprotein Kinetics in T1D NCT05179954NA1 site📍 Columbia University of Missouri-Columbia · Tests: Metabolic testing Low-carbohydrate Diet and Low-Density Lipoprotein - Cholesterol (LDL-c) Interindividual Variability NCT07675603NA1 site📍 Bath University of Bath · Tests: control diet, Low carbohydrate diet Assessment of Compliance With European and French Guidelines for the Management of Dyslipidaemias NCT03449784n/a1 site📍 Montpellier University Hospital, Montpellier · Tests: Detection of patients with dyslipidemia NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia NCT06125847EARLY Phase 11 site📍 Xi'an First Affiliated Hospital Xi'an Jiaotong University · Tests: NGGT006 Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy NCT03512132n/a1 site📍 Dijon Centre Hospitalier Universitaire Dijon · Tests: Blood samples, Urine sample Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial NCT07293260Phase 340 sites📍 Bridgeport📍 Jacksonville📍 Overland Park Amgen · Tests: Olpasiran, Placebo Atlantic Lipid Lowering Treatment Optimization Program NCT06439654NA2 sites📍 Clark📍 Springfield Atlantic Health System · Tests: Supportive care Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels NCT06496243Phase 21 site📍 Philadelphia NewAmsterdam Pharma · Tests: obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy